Compare ALTG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTG | ALXO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.2M | 240.8M |
| IPO Year | N/A | 2020 |
| Metric | ALTG | ALXO |
|---|---|---|
| Price | $6.18 | $1.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $11.33 | $3.50 |
| AVG Volume (30 Days) | 312.1K | ★ 952.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.16 | $0.41 |
| 52 Week High | $8.88 | $2.66 |
| Indicator | ALTG | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 55.15 |
| Support Level | $6.25 | $1.99 |
| Resistance Level | $6.73 | $2.30 |
| Average True Range (ATR) | 0.56 | 0.16 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 8.69 | 69.29 |
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling, Construction Equipment, and Master Distribution. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, Pennsylvania, New York, Florida and throughout the New England States, and The Master Distribution segment is engaged in environmental processing equipment distribution with sub dealers throughout the United States and Canada.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.